CatalystMarker
← board

BKHAU

distress 1/10 · well-funded / low risk
$12.030%today-18% from 52w high
bhspac.comFounded 2023Danville, CAShell Companies
Revenue
pre-revenue
Liquidity
$0M
Runway
Shares 1y
0%

Price & events

+2.8% over 6M
$11.50$13.09$14.69Jan 26Apr 26Jul 2626kfinancing: 8-K private_placement (2026-05-08)financing: 8-K private_placement (2026-02-19)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-3.7%
1W
-0.7%
1M
+2.9%
3M
+2.8%
6M
+14.5%
1Y
+16.2%
2Y
5Y
+18.5%
All

Overview

Market Cap
$49.97M
Volume
0
52 Week Range
$10.51 – $14.69
Total Shares
4.15M
Float Shares
1.24M
% Held by Insiders
0.00%
% Held by Institutions
0.08%
Beta
0.03

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 4,153,577 · 0 offerings/1y · 2 PIPEs
  • 2026-05-088-Kprivate_placement
  • 2026-02-198-Kprivate_placement
  • 2025-07-148-Kmaterial_agreement
  • 2025-04-298-Kmaterial_agreement
  • 2024-11-15SC 13G/Astrategic_stake
  • 2024-11-14SC 13Gstrategic_stake
  • 2024-11-14SC 13Gstrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.